ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern

Yuan, Mengqi; Chen, Xiangyu; Zhu, Yanzhi; Dong, Xiaoqing; Liu, Yan; Qian, Zhaohui*; Ye, Lilin*; Liu, Pinghuang*南方医科大学; 中国医学科学院; 中国农业大学; 中国医学科学院北京协和医院
Journal of Virology2022-8-24DOI: 10.1128/jvi.00775-22
6被引6阅读
引用收藏
分享

摘要

Emerging severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) variants, especially the Omicron variant, have impaired the efficacy of existing vaccines and most therapeutic antibodies, highlighting the need for additional antibody-based tools that can efficiently neutralize emerging SARS-CoV-2 variants. The use of a "single" agent to simultaneously target multiple distinct epitopes on the spike is desirable in overcoming the neutralizing escape of SARS-CoV-2 variants. Herein, we generated a human-derived IgG-like bispecific antibody (bsAb), Bi-Nab(35B5-47D10), which successfully retained parental specificity and simultaneously bound to the two distinct epitopes on receptor-binding domain (RBD) and S2. Bi-Nab(35B5-47D10) showed improved spike binding breadth among wild-type (WT) SARS-CoV-2, variants of concern (VOCs), and variants being monitored (VBMs) compared with its parental monoclonal antibodies (MAbs). Furthermore, pseudotyped virus neutralization demonstrated that Bi-Nab(35B5-47D10) can efficiently neutralize VBMs, including Alpha (B.1.1.7), Beta (B.1.351), and Kappa (B.1.617.1), as well as VOCs, including Delta (B.1.617.2), Omicron BA.1, and Omicron BA.2. Crucially, Bi-Nab(35B5-47D10) substantially improved neutralizing activity against Omicron BA.1 (IC50 = 0.15 nM) and Omicron BA.2 (IC50 = 0.67 nM) compared with its parental MAbs. Therefore, Bi-Nab(35B5-47D10) represents a potential effective countermeasure against SARS-CoV-2 Omicron and other variants of concern. IMPORTANCE The new, highly contagious SARS-CoV-2 Omicron variant caused substantial breakthrough infections and has become the dominant strain in countries across the world. Omicron variants usually bear high mutations in the spike protein and exhibit considerable escape of most potent neutralization monoclonal antibodies and reduced efficacy of current COVID-19 vaccines. The development of neutralizing antibodies with potent efficacy against the Omicron variant is still an urgent priority. Here, we generated a bsAb, Bi-Nab(35B5-47D10,) which simultaneously targets SARS-CoV-2 RBD and S2 and improves the neutralizing potency and breadth against SARS-CoV-2 WT and the tested variants compared with their parental antibodies. Notably, Bi-Nab(35B5-47D10) has more potent neutralizing activity against the VOC Omicron pseudotyped virus. Therefore, Bi-Nab(35B5-47D10) is a feasible and potentially effective strategy by which to treat and prevent COVID-19. @@@ The new, highly contagious SARS-CoV-2 Omicron variant caused substantial breakthrough infections and has become the dominant strain in countries across the world. Omicron variants usually bear high mutations in the spike protein and exhibit considerable escape of most potent neutralization monoclonal antibodies and reduced efficacy of current COVID-19 vaccines.

学科与关键词

关键词
COVID-19SARS-CoV-2bispecific antibodiesOmicron variantsneutralizationneutralizing antibodies
相关
加载中…
  • Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies
    Wang, Yingdan; Zhang, Xiang; Ma, Yunping; Wang, Yanqun; Zhan, Wuqiang; Zheng, Qinwen; Zhang, Meng; Ji, Ping; Liu, Mei; Liu, Qianying; Sun, Tingting; Zhu, Tongyu; Wen, Yumei; Sun, Lei*; Zhao, Jincun*; Wu, Fan*; Chen, Zhenguo*; Huang, Jinghe*Cell Discovery, 2022, 8(1): 104.被引 8
  • Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses
    Wang, Yingdan; Liu, Meiqin; Shen, Yaping; Ma, Yunping; Li, Xiang; Zhang, Yuanyuan; Liu, Mei; Yang, Xing-Lou; Chen, Jun; Yan, Renhong; Luan, Die; Wang, Yanqun; Chen, Ying; Wang, Qimin; Lin, Haofeng; Li, Yaning; Wu, Kaiyue; Zhu, Tongyu; Zhao, Jincun; Lu, Hongzhou; Wen, Yumei; Jiang, Shibo; Wu, Fan; Zhou, Qiang; Shi, Zheng-Li; Huang, JingheCell Discovery, 2022, 8(1): 36.被引 18
  • Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5
    Wang, Yanqun; Yan, An; Song, Deyong; Dong, Chuangchuang; Rao, Muding; Gao, Yuanzhu; Qi, Ruxi; Ma, Xiaomin; Wang, Qiaoping; Xu, Hongguang; Liu, Hong; Han, Jing; Duan, Maoqin; Liu, Shuo; Yu, Xiaoping; Zong, Mengqi; Feng, Jianxia; Jiao, Jie; Zhang, Huimin; Li, Min; Yu, Beibei; Wang, Yanxia; Meng, Fanhao; Ni, Xiaodan; Li, Ying; Shen, Zhenduo; Sun, Baiping; Shao, Xin; Zhao, Haifeng; Zhao, Yanyan; Li, Rui; Zhang, Yanan; Du, Guangying; Lu, Jun; You, Chunna; Jiang, Hua; Zhang, Lu; Wang, Lan*Cell Discovery, 2023, 9(1): 3.被引 7
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Virology
发表日期
2022-08-24
卷期
第 96 卷, 第 16 期
DOI
10.1128/jvi.00775-22
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [32192453]; Chinese Universities Scientific Fund [2022RC019, 2022TC163]

作者

  • Y

    Yuan, Mengqi (第一作者)

    china agr univ

  • C

    Chen, Xiangyu

    southern med univ · third mil med univ, xinqiao hosp

查看全部 8 位作者收起作者
  • Z

    Zhu, Yanzhi

    china agr univ

  • D

    Dong, Xiaoqing

    china agr univ

  • L

    Liu, Yan

    chinese acad med sci · peking union med coll

  • Q

    Qian, Zhaohui (通讯)

    chinese acad med sci · peking union med coll

  • Y

    Ye, Lilin (通讯)

    third mil med univ

  • L

    Liu, Pinghuang (通讯)

    china agr univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417